Steps to the Future: Present and Future of PrEP

This concise MedicalMinute presentation provides an expert overview of approved and guideline-recommended oral HIV PrEP regimens as well as key insights on determining PrEP candidacy and important considerations for specific populations/clinical scenarios, including adolescents, pregnancy/breastfeeding, and transgender individuals.

Darrell H. S. Tan, MD, FRCPC, PhD Physicians: maximum of 0.5 AMA PRA Category 1 Credits™ Released: July 29, 2021 Expired: No longer available for credit

Consider expert perspectives on approved and guideline-recommended oral HIV PrEP regimens as well as key insights on determining PrEP candidacy and important considerations for specific populations/clinical scenarios, including adolescents, pregnancy/breastfeeding, and transgender individuals.

Darrell H. S. Tan, MD, FRCPC, PhD Released: August 4, 2021

This concise MedicalMinute presentation provides an expert overview of investigational long-acting HIV PrEP regimens in late stages of clinical development.

Colleen Kelley, MD, MPH Physicians: maximum of 0.25 AMA PRA Category 1 Credits™ Released: September 20, 2021 Expired: No longer available for credit

Consider expert perspectives on investigational long-acting HIV PrEP regimens in late stages of clinical development.

Colleen Kelley, MD, MPH Released: September 20, 2021

See an expert overview of the different antiretroviral drug formulations and dosing strategies in various stages of clinical development for long-acting HIV PrEP—advances that collectively offer the potential for highly individualized approaches to HIV biomedical prevention.

Nicholas Chamberlain, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits™ Released: October 15, 2021 Expired: No longer available for credit

Consider expert perspectives on the different antiretroviral drug formulations and dosing strategies in various stages of clinical development for long-acting HIV PrEP—advances that collectively offer the potential for highly individualized approaches to HIV biomedical prevention.

Nicholas Chamberlain, MD Released: October 15, 2021

As a person who has chosen to take PrEP to protect myself from HIV infection, here are my thoughts on daily PrEP use, how it has kept me healthy, and what opportunities future PrEP options may offer.

Christian R. Pollard (Patient) Released: November 10, 2021

In this podcast, CCO’s expert faculty discusses approved and guideline-recommended oral HIV PrEP regimens and provides key insights on determining PrEP candidacy and important considerations for specific populations or clinical scenarios, including adolescents, pregnancy/breastfeeding, and transgender individuals.

Darrell H. S. Tan, MD, FRCPC, PhD Released: August 12, 2021

In this podcast, CCO’s expert faculty discusses key features and available safety and efficacy data on investigational long-acting HIV pre-exposure prophylaxis strategies that are in late stages of clinical development.

Colleen Kelley, MD, MPH Released: September 16, 2021

In this podcast, Nicholas Chamberlain, MD, provides an overview of the different antiretroviral drug formulations and dosing strategies in various stages of clinical development for long-acting HIV PrEP—advances that collectively offer the potential for highly individualized approaches to HIV biomedical prevention.

Nicholas Chamberlain, MD Released: October 21, 2021

In this podcast, I share my thoughts as a person who has chosen to take PrEP to protect myself from HIV infection. Listen in on my experience with daily oral PrEP use, how it has kept me healthy, and what opportunities future PrEP options may offer.